NCT07087223 2025-07-25Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI FailurePeking University Cancer Hospital & InstitutePhase 1/2 Recruiting42 enrolled